pulrodemstat (CC-90011) / BMS  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pulrodemstat (CC-90011) / BMS
NCT04350463 / 2019-004194-95: A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Completed
2
92
Europe, US
CC-90011, Nivolumab
Celgene
Neoplasms
12/23
12/23
NCT04748848: A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Terminated
1/2
1
Europe, US
CC-90011, Venetoclax, Azacitidine
Celgene
Leukemia, Myeloid
03/22
03/22

Download Options